Ahmar Jan Qureshi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ahmar Jan Qureshi has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Riyyan Tariq Tagga
CMH Multan Institute of Medical Sciences Multan Pakistan
4 shared publications - Raghabendra Kumar Mahato
Gandaki Medical College Teaching Hospital and Research Center, Pokhara, Nepal
3 shared publications Abat Khan
Memorial Cancer Institute, Pembroke Pines, Florida, USA
1 shared publication- Abdul Qayum Khan
Department of medicine, Saidu Medical College, Swat, Pakistan
1 shared publication Abdul Rafae Faisal
CMH Multan Institute of Medical Sciences, Multan, Pakistan
1 shared publicationAhmad Khan Mudassir
Department of Physiology Shalamar Medical and Dental College Lahore Pakistan
1 shared publication
Latest Publications
- Open Access
- 1 November 2026
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 20 (11) , e70341
Temporal Shifting of Influenza Subtype Dynamics in Pakistan Following the COVID‐19 Pandemic: A 10‐Year FluNet Analysis, 2015–2024
Background: The COVID‐19 pandemic and associated nonpharmaceutical interventions caused unprecedented suppression of influenza circulation globally. Pakistan, with its high population density and evolving surveillance capacity, lacks long‐term data on post‐COVID‐19 influenza patterns, essential for guiding vaccine policy. Methods: We extracted weekly virological data for Pakistan from the WHO FluNet platform (January 1, 2015, to December 31, 2024). The study period was divided into pre‐COVID‐19 (2015–2019), COVID‐19 disruption (2020–2021), and post‐COVID‐19 (2022–2024) phases. Outcomes included type A versus B proportion, subtype distribution (A[H1N1]pdm09 vs. A[H3]), positivity, peak intensity, and season duration (weeks with positivity ≥ 10%). Statistical comparisons used chi‐square for subtype distribution and Kruskal–Wallis for peak intensity. Results: We analyzed 6522 positive specimens from 79,484 tested (10,781 pre‐COVID‐19; 14,687 during COVID‐19 disruption; 54,016 post‐COVID‐19). Influenza A declined from 94.2% to 71.7% then rose to 77.5%; influenza B increased from 5.7% to 28.3%, remaining at 22.5% ( p < 0.001). A(H3) dominated during the COVID‐19 disruption (98.8%); A(H1N1)pdm09 regained dominance post‐COVID‐19 (58.8%), though A(H3) remained higher than pre‐COVID‐19 (41.2% vs. 33.3%). Peak intensity differed ( p = 0.047): pre‐COVID‐19 33.3%–67.6%; COVID‐19 disruption 14.0%–17.6%; and post‐COVID‐19 19.8%–37.8%. Season duration was 1 week in 2020 and 3 non‐consecutive weeks in 2021, versus 10–16 weeks pre‐COVID‐19, recovering to 7–13 weeks post‐COVID‐19. Conclusion: The COVID‐19 pandemic induced a lasting shift in Pakistan's influenza epidemiology, with persistently elevated influenza B and reshaped A subtype balance. These findings are consistent with the global disappearance of B/Yamagata and support consideration of trivalent vaccine formulations, though antigenic and genetic data remain necessary to confirm vaccine match.
- 1 November 2026
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 20 (11) , e70341
Open AccessTemporal Shifting of Influenza Subtype Dynamics in Pakistan Following the COVID‐19 Pandemic: A 10‐Year FluNet Analysis, 2015–2024
Background: The COVID‐19 pandemic and associated nonpharmaceutical interventions caused unprecedented suppression of influenza circulation globally. Pakistan, with its high population density and evolving surveillance capacity, lacks long‐term data on post‐COVID‐19 influenza patterns, essential for guiding vaccine policy. Methods: We extracted weekly virological data for Pakistan from the WHO FluNet platform (January 1, 2015, to December 31, 2024). The study period was divided into pre‐COVID‐19 (2015–2019), COVID‐19 disruption (2020–2021), and post‐COVID‐19 (2022–2024) phases. Outcomes included type A versus B proportion, subtype distribution (A[H1N1]pdm09 vs. A[H3]), positivity, peak intensity, and season duration (weeks with positivity ≥ 10%). Statistical comparisons used chi‐square for subtype distribution and Kruskal–Wallis for peak intensity. Results: We analyzed 6522 positive specimens from 79,484 tested (10,781 pre‐COVID‐19; 14,687 during COVID‐19 disruption; 54,016 post‐COVID‐19). Influenza A declined from 94.2% to 71.7% then rose to 77.5%; influenza B increased from 5.7% to 28.3%, remaining at 22.5% ( p < 0.001). A(H3) dominated during the COVID‐19 disruption (98.8%); A(H1N1)pdm09 regained dominance post‐COVID‐19 (58.8%), though A(H3) remained higher than pre‐COVID‐19 (41.2% vs. 33.3%). Peak intensity differed ( p = 0.047): pre‐COVID‐19 33.3%–67.6%; COVID‐19 disruption 14.0%–17.6%; and post‐COVID‐19 19.8%–37.8%. Season duration was 1 week in 2020 and 3 non‐consecutive weeks in 2021, versus 10–16 weeks pre‐COVID‐19, recovering to 7–13 weeks post‐COVID‐19. Conclusion: The COVID‐19 pandemic induced a lasting shift in Pakistan's influenza epidemiology, with persistently elevated influenza B and reshaped A subtype balance. These findings are consistent with the global disappearance of B/Yamagata and support consideration of trivalent vaccine formulations, though antigenic and genetic data remain necessary to confirm vaccine match.
- Open Access
- 21 July 2026
- Published by Springer Nature in International Journal of Retina and Vitreous
- Vol. 12 (1)
Adjunctive dexamethasone implant during vitrectomy with silicone oil for diabetic tractional retinal detachment: a systematic review and exploratory meta-analysis
Background: Diabetic tractional retinal detachment (TRD) secondary to proliferative diabetic retinopathy is a vision-threatening complication that may require pars plana vitrectomy in selected cases, particularly when the macula is threatened or detached. Silicone oil tamponade is commonly used in complex cases, although tamponade choice varies according to surgical findings and surgeon preference. Objectives: To evaluate surgical outcomes associated with adjunctive dexamethasone implant during pars plana vitrectomy with silicone oil or heavy silicone oil tamponade for diabetic tractional retinal detachment. Methods: A comprehensive literature search of PubMed, Scopus, Web of Science, and ClinicalTrials.gov was performed from inception through 2025. Randomized and non-randomized comparative studies assessing PPV with silicone oil with or without adjunctive dexamethasone implant were considered. Definitions of postoperative PVR and retinal redetachment were accepted as reported by the original studies; no individual-level imaging or independent photographic regrading was available. The anatomical outcome was an exploratory composite of study-reported postoperative proliferative vitreoretinopathy (PVR) and/or retinal redetachment outcomes. Because definitions and follow-up time points differed across studies, this outcome was not treated as a uniformly graded PVR endpoint. Randomized and non-randomized comparative studies were identified; randomized trials were prioritized for the main analysis, while the non-randomized study was considered separately because of serious risk of bias. Secondary outcomes included best-corrected visual acuity (BCVA), central subfield thickness (CST), ocular hypertension, and postoperative complications. The protocol was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO: CRD420261283105) prior to the commencement of the review. Results: Four studies involving 305 eyes were included. In the main randomized-trial analysis, two studies comprising 123 eyes contributed to the exploratory study-reported postoperative proliferative/redetachment composite. The pooled estimate was highly imprecise (RR 0.20, 95% CI 0.00 to 16.06; I² = 0%) and did not provide conclusive evidence of benefit. In an exploratory sensitivity analysis including the non-randomized study, the estimate favored dexamethasone implant, but this analysis was subject to serious risk of bias. BCVA and CST findings were limited by small sample sizes, heterogeneity, and inconsistent reporting. Intraocular-pressure outcomes were not pooled because definitions and assessment time points differed across studies. Conclusion: Current evidence is insufficient to support routine adjunctive dexamethasone implant use during vitrectomy with silicone oil for diabetic tractional retinal detachment. The available studies provide only a hypothesis-generating signal of fewer study-reported postoperative proliferative or redetachment events. Use should remain selective and individualized until adequately powered randomized trials with standardized anatomical outcomes are available. Clinical trials number: Not applicable.
- 21 July 2026
- Published by Springer Nature in International Journal of Retina and Vitreous
- Vol. 12 (1)
Open AccessAdjunctive dexamethasone implant during vitrectomy with silicone oil for diabetic tractional retinal detachment: a systematic review and exploratory meta-analysis
Background: Diabetic tractional retinal detachment (TRD) secondary to proliferative diabetic retinopathy is a vision-threatening complication that may require pars plana vitrectomy in selected cases, particularly when the macula is threatened or detached. Silicone oil tamponade is commonly used in complex cases, although tamponade choice varies according to surgical findings and surgeon preference. Objectives: To evaluate surgical outcomes associated with adjunctive dexamethasone implant during pars plana vitrectomy with silicone oil or heavy silicone oil tamponade for diabetic tractional retinal detachment. Methods: A comprehensive literature search of PubMed, Scopus, Web of Science, and ClinicalTrials.gov was performed from inception through 2025. Randomized and non-randomized comparative studies assessing PPV with silicone oil with or without adjunctive dexamethasone implant were considered. Definitions of postoperative PVR and retinal redetachment were accepted as reported by the original studies; no individual-level imaging or independent photographic regrading was available. The anatomical outcome was an exploratory composite of study-reported postoperative proliferative vitreoretinopathy (PVR) and/or retinal redetachment outcomes. Because definitions and follow-up time points differed across studies, this outcome was not treated as a uniformly graded PVR endpoint. Randomized and non-randomized comparative studies were identified; randomized trials were prioritized for the main analysis, while the non-randomized study was considered separately because of serious risk of bias. Secondary outcomes included best-corrected visual acuity (BCVA), central subfield thickness (CST), ocular hypertension, and postoperative complications. The protocol was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO: CRD420261283105) prior to the commencement of the review. Results: Four studies involving 305 eyes were included. In the main randomized-trial analysis, two studies comprising 123 eyes contributed to the exploratory study-reported postoperative proliferative/redetachment composite. The pooled estimate was highly imprecise (RR 0.20, 95% CI 0.00 to 16.06; I² = 0%) and did not provide conclusive evidence of benefit. In an exploratory sensitivity analysis including the non-randomized study, the estimate favored dexamethasone implant, but this analysis was subject to serious risk of bias. BCVA and CST findings were limited by small sample sizes, heterogeneity, and inconsistent reporting. Intraocular-pressure outcomes were not pooled because definitions and assessment time points differed across studies. Conclusion: Current evidence is insufficient to support routine adjunctive dexamethasone implant use during vitrectomy with silicone oil for diabetic tractional retinal detachment. The available studies provide only a hypothesis-generating signal of fewer study-reported postoperative proliferative or redetachment events. Use should remain selective and individualized until adequately powered randomized trials with standardized anatomical outcomes are available. Clinical trials number: Not applicable.
- 13 May 2026
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 40 (5) , 1-3
Baxdrostat and Aldosterone Synthase Inhibitors: A New Class for Treatment-resistant Hypertension
Purpose To review the mechanistic rationale and recent Phase 3 clinical trial data for baxdrostat, a selective aldosterone synthase inhibitor, in the management of treatment-resistant hypertension. Methods We evaluated efficacy and safety data from the Phase 3 BaxHTN (N = 794) and Bax24 (N = 217) trials, along with a recent systematic review and meta-analysis of aldosterone synthase inhibitors. Results In BaxHTN, baxdrostat 2 mg reduced seated systolic blood pressure by -15.7 mmHg (placebo-adjusted − 9.8 mmHg; P < 0.001). In Bax24, 24-hour ambulatory systolic blood pressure decreased by -16.6 mmHg (placebo-adjusted − 14.0 mmHg; P < 0.001). Hyperkalemia (> 5.5 mmol/L) occurred in approximately 12% of baxdrostat-treated patients versus 3% with placebo, with low discontinuation rates (approximately 2%). No cortisol suppression or adrenal insufficiency was observed. Conclusion Baxdrostat has demonstrated among the largest ambulatory blood pressure reductions reported in contemporary treatment-resistant hypertension trials. With FDA Priority Review underway (PDUFA Q2 2026), this first-in-class agent represents a potential therapeutic advancement for patients inadequately controlled on existing regimens.
- 13 May 2026
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 40 (5) , 1-3
Baxdrostat and Aldosterone Synthase Inhibitors: A New Class for Treatment-resistant Hypertension
Purpose To review the mechanistic rationale and recent Phase 3 clinical trial data for baxdrostat, a selective aldosterone synthase inhibitor, in the management of treatment-resistant hypertension. Methods We evaluated efficacy and safety data from the Phase 3 BaxHTN (N = 794) and Bax24 (N = 217) trials, along with a recent systematic review and meta-analysis of aldosterone synthase inhibitors. Results In BaxHTN, baxdrostat 2 mg reduced seated systolic blood pressure by -15.7 mmHg (placebo-adjusted − 9.8 mmHg; P < 0.001). In Bax24, 24-hour ambulatory systolic blood pressure decreased by -16.6 mmHg (placebo-adjusted − 14.0 mmHg; P < 0.001). Hyperkalemia (> 5.5 mmol/L) occurred in approximately 12% of baxdrostat-treated patients versus 3% with placebo, with low discontinuation rates (approximately 2%). No cortisol suppression or adrenal insufficiency was observed. Conclusion Baxdrostat has demonstrated among the largest ambulatory blood pressure reductions reported in contemporary treatment-resistant hypertension trials. With FDA Priority Review underway (PDUFA Q2 2026), this first-in-class agent represents a potential therapeutic advancement for patients inadequately controlled on existing regimens.
- Open Access
- 30 April 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (3) , e70230
Methodological Shortcomings in a Study of Peripheral Circulatory Complications in Type 2 Diabetes
Introduction: This critique examines the methodological quality of a recent study by Shahid et al. on mortality trends related to peripheral circulatory complications in patients with type 2 diabetes mellitus using the CDC WONDER database. Methods: We critically appraised the original study's methodology, including the consistency of reported mortality rates, age group data presentation, classification of urban and rural areas, reporting of race and ethnicity data, place of death analysis and causal inferences drawn from the ecological design. Results: Several methodological shortcomings were identified: inconsistent reporting of mortality rate denominators (per 100,000 vs. per 1,000,000 population); selective reporting of age group data in the main text; use of a non‐standard threshold (500,000 population) for classifying urban and rural areas; inconsistent use of the ‘Non‐Hispanic’ qualifier for race and ethnicity categories; percentages summing to over 100% in the place of death analysis; and unsupported causal claims in the discussion. Conclusions: While the original study addresses an important public health concern, the identified methodological issues limit the interpretability of its findings. Addressing these concerns through consistent denominators, complete age‐stratified reporting and standard classifications would strengthen future research in this area.
- 30 April 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (3) , e70230
Open AccessMethodological Shortcomings in a Study of Peripheral Circulatory Complications in Type 2 Diabetes
Introduction: This critique examines the methodological quality of a recent study by Shahid et al. on mortality trends related to peripheral circulatory complications in patients with type 2 diabetes mellitus using the CDC WONDER database. Methods: We critically appraised the original study's methodology, including the consistency of reported mortality rates, age group data presentation, classification of urban and rural areas, reporting of race and ethnicity data, place of death analysis and causal inferences drawn from the ecological design. Results: Several methodological shortcomings were identified: inconsistent reporting of mortality rate denominators (per 100,000 vs. per 1,000,000 population); selective reporting of age group data in the main text; use of a non‐standard threshold (500,000 population) for classifying urban and rural areas; inconsistent use of the ‘Non‐Hispanic’ qualifier for race and ethnicity categories; percentages summing to over 100% in the place of death analysis; and unsupported causal claims in the discussion. Conclusions: While the original study addresses an important public health concern, the identified methodological issues limit the interpretability of its findings. Addressing these concerns through consistent denominators, complete age‐stratified reporting and standard classifications would strengthen future research in this area.
- Open Access
- 21 April 2026
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 47, 101222
HHV-6 reactivation in the era of CAR T-cell therapy: A systematic review of emerging challenges
- 21 April 2026
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 47, 101222
Open AccessHHV-6 reactivation in the era of CAR T-cell therapy: A systematic review of emerging challenges
- Open Access
- 11 April 2026
- Published by Elsevier in American Heart Journal Plus: Cardiology Research and Practice
- Vol. 65, 100780
Methodological concerns regarding mortality trends in CVD and Alzheimer's disease comorbidity
- 11 April 2026
- Published by Elsevier in American Heart Journal Plus: Cardiology Research and Practice
- Vol. 65, 100780
Open AccessMethodological concerns regarding mortality trends in CVD and Alzheimer's disease comorbidity
- Open Access
- 6 January 2026
- Published by Wiley in Precision Medical Sciences
- Vol. 15 (1) , 42-56
Biomarker‐based long‐term safety and efficacy of PD ‐1/ PD ‐ L1 inhibitors combined with chemotherapy in advanced gastroesophageal carcinomas: A systematic review and meta‐analysis
Advanced gastroesophageal cancers often have poor survival rates even with chemotherapy. We aim to study the long‐term safety and efficacy of combining PD‐1/PD‐L1 inhibitors with chemotherapy, incorporating biomarker analysis and recent Phase III trial data. Data from eight phase III trials (from inception to 2025, comprising 5668 patients) was combined in this PRISMA‐guided meta‐analysis. Overall survival (OS), objective response rate (ORR), progression‐free survival (PFS), and grade ≥3 adverse events were among the outcomes. Random‐effects models were employed for statistical synthesis, and I 2 was used to assess the heterogeneity. Cochrane RoB 2.0 was used to evaluate the risk of bias. Compared to chemotherapy alone, the combined regimen significantly improved overall survival (HR: 0.79; 95% CI: 0.75–0.83; p < .0001), progression‐free survival (HR: 0.73; 95% CI: 0.68–0.78; p < .00001), and objective response rate (OR: 1.60; 95% CI: 1.44–1.78; p < .0001). The CPS ≥10 subgroups showed the greatest benefits (OS HR, 0.66; PFS HR, 0.63; p < .0001). Although manageable, grade ≥3 adverse events (OR, 1.37; 95% CI: 1.20–1.56) and immune‐related toxicities (OR: 3.44; 95% CI: 2.91–4.08) were more common with ICIs. The OS advantage was greatest for MSI‐high tumors (HR: 0.54; p < .04), but was not significant for esophageal cancers (HR: 0.88; p < .18). With long‐lasting improvements in survival and manageable toxicity, PD‐1/PD‐L1 inhibitors in combination with chemotherapy constitute the first‐line standard for advanced gastric/GEJ malignancies. Immune checkpoint inhibitors show a higher incidence of adverse events, and clinicians should balance efficacy against adverse event risk.
- 6 January 2026
- Published by Wiley in Precision Medical Sciences
- Vol. 15 (1) , 42-56
Open AccessBiomarker‐based long‐term safety and efficacy of PD ‐1/ PD ‐ L1 inhibitors combined with chemotherapy in advanced gastroesophageal carcinomas: A systematic review and meta‐analysis
Advanced gastroesophageal cancers often have poor survival rates even with chemotherapy. We aim to study the long‐term safety and efficacy of combining PD‐1/PD‐L1 inhibitors with chemotherapy, incorporating biomarker analysis and recent Phase III trial data. Data from eight phase III trials (from inception to 2025, comprising 5668 patients) was combined in this PRISMA‐guided meta‐analysis. Overall survival (OS), objective response rate (ORR), progression‐free survival (PFS), and grade ≥3 adverse events were among the outcomes. Random‐effects models were employed for statistical synthesis, and I 2 was used to assess the heterogeneity. Cochrane RoB 2.0 was used to evaluate the risk of bias. Compared to chemotherapy alone, the combined regimen significantly improved overall survival (HR: 0.79; 95% CI: 0.75–0.83; p < .0001), progression‐free survival (HR: 0.73; 95% CI: 0.68–0.78; p < .00001), and objective response rate (OR: 1.60; 95% CI: 1.44–1.78; p < .0001). The CPS ≥10 subgroups showed the greatest benefits (OS HR, 0.66; PFS HR, 0.63; p < .0001). Although manageable, grade ≥3 adverse events (OR, 1.37; 95% CI: 1.20–1.56) and immune‐related toxicities (OR: 3.44; 95% CI: 2.91–4.08) were more common with ICIs. The OS advantage was greatest for MSI‐high tumors (HR: 0.54; p < .04), but was not significant for esophageal cancers (HR: 0.88; p < .18). With long‐lasting improvements in survival and manageable toxicity, PD‐1/PD‐L1 inhibitors in combination with chemotherapy constitute the first‐line standard for advanced gastric/GEJ malignancies. Immune checkpoint inhibitors show a higher incidence of adverse events, and clinicians should balance efficacy against adverse event risk.
- Open Access
- 20 December 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 1198-1199
Epinephrine nasal spray for anaphylaxis: a preferred needle-free self-treatment
Anaphylaxis is a rapid-onset, potentially fatal allergic reaction that requires immediate epinephrine administration. Traditional intramuscular auto-injectors can be hindered by needle phobia, incorrect use, limited availability, and injection-related injuries. Neffy, the first FDA-approved intranasal epinephrine spray, provides a needle-free, rapid, and user-friendly alternative. Its nasal formulation allows swift absorption, producing pharmacodynamic effects within one minute, comparable to conventional auto-injectors. By eliminating needles, Neffy reduces the risk of lacerations, ischemic complications, and accidental injuries, while enhancing adherence among patients or caregivers hesitant to use injections. Early data indicate effective management of anaphylaxis with this device, though further studies in broader populations are warranted. Adoption of nasal epinephrine may improve timely treatment, increase accessibility, and offer a safer, patient-centered approach to emergency allergic reactions.
- 20 December 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 1198-1199
Open AccessEpinephrine nasal spray for anaphylaxis: a preferred needle-free self-treatment
Anaphylaxis is a rapid-onset, potentially fatal allergic reaction that requires immediate epinephrine administration. Traditional intramuscular auto-injectors can be hindered by needle phobia, incorrect use, limited availability, and injection-related injuries. Neffy, the first FDA-approved intranasal epinephrine spray, provides a needle-free, rapid, and user-friendly alternative. Its nasal formulation allows swift absorption, producing pharmacodynamic effects within one minute, comparable to conventional auto-injectors. By eliminating needles, Neffy reduces the risk of lacerations, ischemic complications, and accidental injuries, while enhancing adherence among patients or caregivers hesitant to use injections. Early data indicate effective management of anaphylaxis with this device, though further studies in broader populations are warranted. Adoption of nasal epinephrine may improve timely treatment, increase accessibility, and offer a safer, patient-centered approach to emergency allergic reactions.
- Open Access
- 20 February 2025
- Published by Wiley
First-generation antihistamine and seizure risk in pediatrics: A call to awareness
Antihistamines are commonly used to treat allergic diseases in children, such as rhinitis, asthma, and urticaria. They are classified into first and second-generation. First-generation antihistamines can cross the blood-brain barrier, causing significant sedation and other side effects, including new-onset seizures, poor academic performance, and paradoxical agitation. Recent studies show an increased risk of seizures, particularly in children aged 6 to 24 months. Although effective, first-generation antihistamines pose serious risks like sedation, cognitive impairment, and increased seizure risk. It is recommended to use newer, nonsedating antihistamines, which have fewer side effects. Children under six years old, especially those under two, should not be given first-generation antihistamines, particularly during flu season.
- 20 February 2025
- Published by Wiley
Open AccessFirst-generation antihistamine and seizure risk in pediatrics: A call to awareness
Antihistamines are commonly used to treat allergic diseases in children, such as rhinitis, asthma, and urticaria. They are classified into first and second-generation. First-generation antihistamines can cross the blood-brain barrier, causing significant sedation and other side effects, including new-onset seizures, poor academic performance, and paradoxical agitation. Recent studies show an increased risk of seizures, particularly in children aged 6 to 24 months. Although effective, first-generation antihistamines pose serious risks like sedation, cognitive impairment, and increased seizure risk. It is recommended to use newer, nonsedating antihistamines, which have fewer side effects. Children under six years old, especially those under two, should not be given first-generation antihistamines, particularly during flu season.